JP2002527397A5 - - Google Patents

Download PDF

Info

Publication number
JP2002527397A5
JP2002527397A5 JP2000575514A JP2000575514A JP2002527397A5 JP 2002527397 A5 JP2002527397 A5 JP 2002527397A5 JP 2000575514 A JP2000575514 A JP 2000575514A JP 2000575514 A JP2000575514 A JP 2000575514A JP 2002527397 A5 JP2002527397 A5 JP 2002527397A5
Authority
JP
Japan
Prior art keywords
agent
functional equivalent
amiloride analog
hma
functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000575514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527397A (ja
JP4624562B2 (ja
Filing date
Publication date
Priority claimed from AUPP6464A external-priority patent/AUPP646498A0/en
Application filed filed Critical
Publication of JP2002527397A publication Critical patent/JP2002527397A/ja
Publication of JP2002527397A5 publication Critical patent/JP2002527397A5/ja
Application granted granted Critical
Publication of JP4624562B2 publication Critical patent/JP4624562B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000575514A 1998-10-12 1999-10-12 イオンチャネル機能活性の調節方法 Expired - Fee Related JP4624562B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP6464A AUPP646498A0 (en) 1998-10-12 1998-10-12 A method of modulating ion channel functional activity
AU6464 1998-10-12
PCT/AU1999/000872 WO2000021538A1 (en) 1998-10-12 1999-10-12 A method of modulating ion channel functional activity

Publications (3)

Publication Number Publication Date
JP2002527397A JP2002527397A (ja) 2002-08-27
JP2002527397A5 true JP2002527397A5 (cg-RX-API-DMAC10.html) 2007-01-25
JP4624562B2 JP4624562B2 (ja) 2011-02-02

Family

ID=3810686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000575514A Expired - Fee Related JP4624562B2 (ja) 1998-10-12 1999-10-12 イオンチャネル機能活性の調節方法

Country Status (8)

Country Link
US (2) US7179803B1 (cg-RX-API-DMAC10.html)
EP (1) EP1121128B1 (cg-RX-API-DMAC10.html)
JP (1) JP4624562B2 (cg-RX-API-DMAC10.html)
CN (1) CN1245161C (cg-RX-API-DMAC10.html)
AU (1) AUPP646498A0 (cg-RX-API-DMAC10.html)
CA (1) CA2345896C (cg-RX-API-DMAC10.html)
NZ (1) NZ510437A (cg-RX-API-DMAC10.html)
WO (1) WO2000021538A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10210206A1 (de) * 2002-03-01 2003-09-04 Florian Lang Fertilitätsreduzierung bei Vertebraten
AU2003903251A0 (en) * 2003-06-26 2003-07-10 Biotron Limited Antiviral compounds and methods
EP1646371A4 (en) * 2003-06-26 2010-09-22 Biotron Ltd ANTIVIRAL COMPOSITIONS AND METHODS
WO2006130806A2 (en) * 2005-06-01 2006-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Assay for agonists and antagonists of ion channels and for regulators of genetic expression
CN112156753A (zh) * 2020-09-23 2021-01-01 中国石油大学(华东) 石墨烯气凝胶及其制备方法和应用
CN121872955B (zh) * 2026-03-17 2026-07-24 安徽纽健生物科技有限公司 3-氨基异丁酸衍生物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085211A (en) * 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
WO1990009792A1 (en) * 1989-03-03 1990-09-07 The General Hospital Corporation Topical application of amiloride or analogues thereof for treatment of inflammation
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
JPH0725768A (ja) 1993-07-09 1995-01-27 Mitsubishi Chem Corp 血管内膜肥厚抑制剤
JPH10500669A (ja) * 1994-04-12 1998-01-20 アルザ・コーポレーション サイトカイン阻害薬に関するスクリーニング法
AUPO258196A0 (en) * 1996-09-27 1996-10-17 Australian National University, The Method for determining ion channel activity of a substance

Similar Documents

Publication Publication Date Title
Lalezari et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS
JP2023526836A5 (cg-RX-API-DMAC10.html)
JP5470047B2 (ja) 抗ウイルス組成物及び使用方法
JP2009504157A5 (cg-RX-API-DMAC10.html)
JPH0676317B2 (ja) 抗ウイルス医薬製剤およびその使用法
CA2398335A1 (en) Herpes virus strains
JP2001515712A5 (cg-RX-API-DMAC10.html)
Winston et al. Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer
CN103079561B (zh) 用于预防hsv-2传播的局部用抗病毒制剂
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
WO2001034177A3 (en) Method of treating a viral infection using antagonists of macrophage colony stimulating factor
Vella et al. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity.
Tyring Immune-response modifiers: a new paradigm in the treatment of human papillomavirus
Harris et al. The activity of iododeoxyuridine, adenine arabinoside, cytosine arabinoside, ribavirin and phosphonoacetic acid against herpes virus in the hairless mouse model
Wintergerst et al. Effect of recombinant human interferon α B/D (rHu-IFN-α B/D) in combination with acyclovir in experimental HSV-1 encephalitis
JP2013542206A (ja) Ｃ型肝炎ウイルス感染症の新規治療
JP6110791B2 (ja) Ｃ型肝炎ウイルス感染症の新規治療
WO2000030626A2 (en) Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
WO2013120414A1 (zh) Hiv杀微生物剂及其应用
Siliciano HARRT for life
JP2004155777A (ja) Ｃ型慢性肝炎治療剤
Naoum et al. Treatment of herpes zoster with interferon alpha-2A.
Mindel Treatment and prevention of genital herpes
James 1592--new experimental antiretroviral
Tyrrell et al. Prophylaxis and treatment of rhinovirus infections